Table 4.
ST2 Concentration (continuous) and cardiovascular outcomes per log increase in ST2.
| 30-Day follow-up
|
1-Year follow-up
|
|||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| All-cause mortality | ||||
|
| ||||
| Unadjusted | 1.79 (1.50–2.13) | <0.001 | 1.56 (1.41–1.73) | <0.001 |
|
| ||||
| Adjusteda | 1.45 (1.19–1.76) | <0.001 | 1.26 (1.12–1.40) | <0.001 |
|
| ||||
| CVD | ||||
|
| ||||
| Unadjusted | 1.74 (1.45–2.10) | <0.001 | 1.51 (1.35–1.69) | <0.001 |
|
| ||||
| Adjusted | 1.39 (1.13–1.70) | 0.002 | 1.19 (1.06–1.34) | 0.004 |
|
| ||||
| New or worsening HF | ||||
|
| ||||
| Unadjusted | 1.83 (1.58–2.12) | <0.001 | 1.72 (1.54–1.92) | <0.001 |
|
| ||||
| Adjusted | 1.47 (1.25–1.74) | <0.001 | 1.37 (1.21–1.55) | <0.001 |
|
| ||||
| CVD/HF | ||||
|
| ||||
| Unadjusted | 1.80 (1.58–2.04) | <0.001 | 1.56 (1.43–1.71) | <0.001 |
|
| ||||
| Adjusted | 1.43 (1.24–1.65) | <0.001 | 1.25 (1.13–1.38) | <0.001 |